Susan is 66. Her doctor told her the cartilage in her right knee is nearly gone. The only option on the table is a joint replacement. Not because her body doesn’t know how to repair itself — but because one enzyme keeps stopping it.

That enzyme is called 15-PGDH (15-hydroxyprostaglandin dehydrogenase). It isn’t a household name. Until a few years ago, it was studied almost exclusively in specialized research laboratories. Then, between 2020 and 2025, a series of studies published in Science, PNAS, Nature Communications, and the Journal of Medicinal Chemistry reframed the picture.

15-PGDH is a negative regulator of tissue regeneration. It degrades prostaglandin E2 (PGE2), the molecule the body uses to signal damaged tissue to begin repairing. Its levels roughly double with aging. The practical consequence: the older you get, the faster your body neutralizes its own repair signal — not due to lack of capacity, but because this enzyme breaks down the message before it reaches its target.

Blocking 15-PGDH reactivates that signal. The data show it works.

What 15-PGDH does and why its age-related rise is a problem

Understanding why 15-PGDH matters requires stepping back from the common association between prostaglandins and inflammation. PGE2 does promote inflammation in some contexts — but it is also a central signal for tissue repair. When tissue sustains damage, PGE2 activates local stem cells, promotes the proliferation of tissue-specific progenitors, and initiates regeneration.

15-PGDH works in the opposite direction. It catalyzes the first step in PGE2 degradation by oxidizing a specific hydroxyl group and rendering the molecule inactive — unable to bind its receptors. This mechanism was mapped in detail by Huang W. et al. in a 2023 study published in Nature Communications, where cryo-electron microscopy resolved the three-dimensional structure of 15-PGDH both in its native state and bound to two different inhibitors. The researchers identified a dynamic lid domain that closes around the inhibitors, and two residues — F185 and Y217 — that act as hinges, explaining the sub-nanomolar binding affinities of the most potent compounds.

The issue is not that 15-PGDH exists — the body needs to eventually shut down repair signals once healing is complete. The issue is that levels of this enzyme roughly double with aging, creating a chronic imbalance. The repair signal gets turned off too early, before tissues have had adequate time to regenerate.

Researchers have called 15-PGDH a gerozyme — an enzyme that actively drives age-related tissue deterioration. The lead small molecule inhibitor studied, SW033291, doubles tissue PGE2 levels and has accelerated regeneration across multiple organs in murine models: bone marrow, colon, liver, lung, muscle, cartilage, and brain. The same biological mechanism; different target tissues.

For more on the immune mechanisms driving joint deterioration, see our article on osteoarthritis and the immune system.

Cartilage regeneration: the data that change how we think about osteoarthritis

The most recent and clinically significant application involves articular cartilage. The study by Singla M. et al., published in Science in November 2025, is the first to show that a 15-PGDH inhibitor produces cartilage regeneration in aging and injury animal models and produces equivalent changes in human cartilage explants from knee replacement patients.

Key findings from the study:

• In aging mice, previously thinned cartilage thickened following treatment, returning to a morphology resembling that of young animals.
• In young mice with ACL-equivalent injuries, the inhibitor prevented arthritis development in *50% of cases*.
• Regenerated cartilage was hyaline articular cartilage — not the functionally inferior fibrocartilage — confirmed by collagen II and specific proteoglycan synthesis.
• Pain scores, measured using three validated behavioral tests, were significantly reduced.
• Single-cell RNA sequencing and spatial proteomics identified a population of hypertrophic chondrocytes expressing 15-PGDH aberrantly in osteoarthritic joints. Treatment reduced this population and increased matrix-secreting chondrocytes.

What stands out is the mechanism. This regeneration does not rely on stem cell proliferation or the recruitment of new cells. The chondrocytes already present in the joint shift their gene expression pattern — a form of local cellular reprogramming with no prior precedent in orthopedic pharmacology.

Stanford’s Dr. Nidhi Bhutani, senior author of the study, described the inhibitor as producing more dramatic cartilage regeneration than any previously reported drug or intervention, with the explicit goal of avoiding total joint replacement.

For patients who currently have no options beyond surgery — tens of millions worldwide, at an estimated cost of $65 billion annually in the US alone — this is a concrete development. No approved drug currently slows or reverses osteoarthritis. For current regenerative approaches, see our article on stem cell therapy for knee osteoarthritis.

Muscle and sarcopenia: already in clinical trials

Research on 15-PGDH inhibition for muscle preceded the cartilage work. The study by Palla AR et al., published in Science in 2020, identified 15-PGDH as a molecular driver of sarcopenia — the progressive loss of muscle mass and strength that accompanies aging.

PGE2 is required for the activation and expansion of muscle satellite cells — the precursors that repair tissue after exercise or injury. As 15-PGDH levels rise with age, PGE2 is degraded too rapidly. Satellite cells don’t receive the signal, the muscle doesn’t repair, and mass declines.

Blocking 15-PGDH with SW033291 in aging mice produced measurable increases in muscle mass and strength. Artificially expressing 15-PGDH in young mice caused muscle atrophy — the direct inverse. The relationship is causal, not merely correlational.

The clinical translation arrived with MF-300, an oral inhibitor developed by Epirium Bio. Data from Webster M. et al. in 2024, published in Innovation in Aging, show that MF-300 improves fast-twitch muscle fiber quality in aging mice — increasing specific force (force per unit mass) independently of any increase in muscle volume.

Phase 1 in healthy volunteers was completed with no safety signals. Epirium Bio has received written feedback from the FDA on the Phase 2b trial design. That documented safety profile will likely accelerate clinical progression for cartilage as well.

For nutritional strategies to support muscle health in aging, see our article on protein after 45.

Brain, kidney, heart, and liver: the same mechanism, different organs

15-PGDH is present in nearly all tissues, and its age-related increase is systemic. Multiple research groups have tested its inhibition in organs beyond cartilage and muscle. The results are consistent.

Alzheimer’s disease and traumatic brain injury

Koh et al., in PNAS in May 2025, showed that 15-PGDH is pathologically elevated in the brains of Alzheimer’s patients, after traumatic brain injury, and in murine models of both conditions. SW033291 treatment in 5xFAD mice produced four specific results:

• Complete protection of the blood-brain barrier from progressive deterioration.
• Full prevention of cognitive impairment in spatial memory tests (Morris Water Maze).
• Reduced neuroinflammation and reactive oxygen species.
• No effect on amyloid deposition — a mechanistically distinct approach from recently approved anti-amyloid drugs.

That last point has direct clinical implications. If part of Alzheimer’s cognitive damage stems from neuroinflammation and blood-brain barrier breakdown rather than amyloid alone, a drug acting on this second mechanism could benefit patients who don’t respond to amyloid-targeting therapies. For a broader picture of Alzheimer’s biology, see our article on Alzheimer’s disease pathology.

Kidney

Kim HJ et al., in the American Journal of Physiology – Renal Physiology in 2020, showed that prophylactic SW033291 significantly reduced acute kidney injury from ischemia-reperfusion in mice. Creatinine, blood urea nitrogen, NGAL, and KIM-1 — all standard markers of kidney damage — dropped significantly. A single prophylactic dose was sufficient to produce the protective effect.

Heart

A 2025 study showed SW033291 attenuates age-related heart failure in mice by activating Notch signaling and reducing aberrant 15-PGDH expression in cardiac tissue.

Liver (MASH)

Udoh US et al., in Cells in 2025, reported that SW033291 reduces MASH progression in mice with precise measurements: the NAS score dropped from 9.4 ± 0.2 to 6.2 ± 0.1; liver fibrosis score from 1.3 ± 0.5 to 0.25 ± 0.1; apoptotic activity from 43.9% to 0.38%. These changes were accompanied by reductions in total body fat, oxidative stress, and inflammation, with improved insulin resistance.

How new inhibitors are being designed

SW033291, the most studied compound, inhibits 15-PGDH with a Ki of 0.1 nM — an exceptionally low value indicating very high binding affinity. The 2023 structural study in Nature Communications explained why: the inhibitors capture the enzyme’s mobile lid domain in a closed conformation, exploiting F185 and Y217 as anchor residues. The cryo-EM structure identified the binding sites at sub-nanometer precision.

In 2025, two further studies in the Journal of Medicinal Chemistry raised the bar. Dodda LS et al. used advanced computational methods — FEP+ and WaterMap — alongside a machine learning model trained on predicted binding potencies to guide chemical synthesis. The resulting lead compound elevated colonic PGE2 in mice. Li Q. et al. described HW201877, a highly potent and orally bioavailable inhibitor with improved pharmacokinetics over SW033291.

This progression — from a high-throughput screening hit to rationally designed molecules guided by AI — is the normal maturation cycle of a validated drug target. It means the biology is confirmed and the chemistry is in optimization.

For background on the cellular mechanisms of aging, see our article on aging theories.

Where the research stands and what it means for patients

In five years, research on 15-PGDH moved from a mechanism discovered in one tissue to a picture spanning cartilage, muscle, brain, kidney, heart, and liver. Each study used different models, different endpoints, and confirmed the same finding: blocking 15-PGDH raises tissue PGE2 and produces measurable regeneration.

The oral drug MF-300 cleared Phase 1 in healthy humans. The Stanford Science paper has already generated a patent application through the university for 15-PGDH inhibition in cartilage regeneration. The next step is a clinical trial in osteoarthritis patients.

For patients like Susan — who are waiting for an answer that isn’t joint replacement — this is not yet a prescription they can fill. But it is the most biologically grounded active research program in regenerative medicine for a condition affecting 1 in 5 adults. The mechanism is real, the Phase 1 safety data is encouraging, and the human tissue findings are direct. The gap between here and clinical availability is clinical trials — and those are now in preparation.

References

1. Singla M et al. Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration. Science. 2025;391(6789). DOI: 10.1126/science.adx6649

2. Palla AR et al. Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength. Science. 2020. DOI: 10.1126/science.abc8059

3. Koh et al. Inhibiting 15-PGDH blocks blood-brain barrier deterioration and protects mice from Alzheimer’s disease and traumatic brain injury. Proc Natl Acad Sci USA. 2025;122:e2417224122. DOI: 10.1073/pnas.2417224122

4. Udoh US et al. Inhibition of the prostaglandin-degrading enzyme 15-PGDH ameliorates MASH-associated apoptosis and fibrosis in mice. Cells. 2025;14(13):987. DOI: 10.3390/cells14130987

5. Huang W et al. Small molecule inhibitors of 15-PGDH exploit a physiologic induced-fit closing system. Nat Commun. 2023;14(1):784. DOI: 10.1038/s41467-023-36463-7

6. Kim HJ et al. Inhibition of 15-PGDH prevents ischemic renal injury by the PGE2/EP4 signaling pathway. Am J Physiol Renal Physiol. 2020;319(6):F1054-F1066. DOI: 10.1152/ajprenal.00103.2020

7. Webster M et al. MF-300 (15-PGDH enzyme inhibitor) reverses age-related muscle weakness in mice by restoring muscle quality. Innovation in Aging. 2024. DOI: 10.1093/geroni/igae098.3672

8. Smith JN et al. 15-PGDH inhibition activates the splenic niche to promote hematopoietic regeneration. JCI Insight. 2021;6(6):e143658. DOI: 10.1172/jci.insight.143658

9. Mallipeddi PL et al. Structural Insights into Novel 15-Prostaglandin Dehydrogenase Inhibitors. Molecules. 2021;26(19):5903. DOI: 10.3390/molecules26195903

10. Huang Y et al. Investigating the Mechanisms of 15-PGDH Inhibitor SW033291 in Improving Type 2 Diabetes Mellitus. Metabolites. 2024;14(9):509. DOI: 10.3390/metabo14090509

11. Dodda LS et al. Knowledge and Structure-Based Drug Design of 15-PGDH Inhibitors. J Med Chem. 2025;68(17):18436-18462. DOI: 10.1021/acs.jmedchem.5c01231

12. Li Q et al. Discovery of HW201877: A Highly Potent and Orally Bioavailable Inhibitor of 15-Prostaglandin Dehydrogenase. J Med Chem. 2025;68(13):14099-113.